

Montserrat Muñoz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1327540/publications.pdf>

Version: 2024-02-01

105
papers

5,097
citations

101543

36
h-index

95266

68
g-index

108
all docs

108
docs citations

108
times ranked

7680
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	2.2	735
2	Preoperative Staging of Large Primary Breast Cancer With [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Compared With Conventional Imaging Procedures. <i>Journal of Clinical Oncology</i> , 2008, 26, 4746-4751.	1.6	259
3	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 545-554.	10.7	250
4	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. <i>Cell Reports</i> , 2014, 6, 514-527.	6.4	239
5	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	5.0	175
6	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	27.0	169
7	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2213-2221.	0.9	168
8	Gender, age, socio-demographic and lifestyle factors associated with major dietary patterns in the Spanish Project SUN (Seguimiento Universidad de Navarra). <i>European Journal of Clinical Nutrition</i> , 2003, 57, 285-292.	2.9	164
9	A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 811-816.	7.0	113
10	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015, 13, 303.	5.5	113
11	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	1.6	108
12	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 33-43.	10.7	105
13	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. <i>Breast Cancer Research and Treatment</i> , 1998, 51, 109-119.	2.5	104
14	¹⁸ F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1551-1557.	6.4	104
15	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. <i>Nature Cell Biology</i> , 2018, 20, 211-221.	10.3	98
16	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016, 2, 1287.	7.1	96
17	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
18	Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 3030-3038.	1.6	90

#	ARTICLE	IF	CITATIONS
19	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 63-70.	7.7	79
20	Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 715-721.	0.8	75
21	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , The, 2011, 12, 369-376.	10.7	73
22	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 1148-1157.	3.2	70
23	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	12.8	67
24	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. <i>British Journal of Cancer</i> , 1996, 74, 1126-1131.	6.4	64
25	CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS. , 1997, 182, 160-166.		63
26	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. <i>Tumor Biology</i> , 2010, 31, 171-180.	1.8	61
27	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 507-515.	2.5	60
28	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795.	1.6	56
29	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0126096.	2.5	56
30	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2593-2599.	1.6	52
31	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
32	SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1229-1236.	2.4	51
33	Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based Chemotherapy. <i>Oncology</i> , 2004, 66, 388-394.	1.9	48
34	Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors. <i>Medical Oncology</i> , 2014, 31, 783.	2.5	47
35	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. <i>Journal of Pathology</i> , 1998, 184, 265-271.	4.5	46
36	Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 62-72.	4.4	41

#	ARTICLE	IF	CITATIONS
37	Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. <i>Breast</i> , 2014, 23, 710-720.	2.2	37
38	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017, 144, 577-585.	1.4	34
39	Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. <i>British Journal of Cancer</i> , 2009, 100, 442-449.	6.4	33
40	The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. <i>PLoS ONE</i> , 2016, 11, e0159672.	2.5	32
41	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	3.7	29
42	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. <i>Annals of Oncology</i> , 2011, 22, 2591-2596.	1.2	28
43	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	7.0	28
44	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. <i>Environment International</i> , 2019, 122, 389-399.	10.0	28
45	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019, 17, 8.	5.5	28
46	Circulating levels of HER-2/neu oncoprotein in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 5-21.	2.3	27
47	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2016, 116, 1914-1924.e6.	0.8	26
48	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017, 8, 73144-73153.	1.8	24
49	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2022, 16, 69-87.	4.6	24
50	MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells. <i>Oncotarget</i> , 2017, 8, 83384-83406.	1.8	23
51	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019, 9, 3904.	3.3	23
52	Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, 701-709.	7.7	21
53	Predicting Non-Sentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Involvement: Evaluation of Two Scoring Systems. <i>Breast Journal</i> , 2010, 16, 134-140.	1.0	21
54	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. <i>Oncologist</i> , 2015, 20, 111-112.	3.7	20

#	ARTICLE	IF	CITATIONS
55	Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors. <i>European Journal of Cancer Care</i> , 2018, 27, e12861.	1.5	20
56	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2 ⁻) early breast cancer (EBC): results from the GEICAM/2006-10 study. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 115-125.	2.5	20
57	Ingested Nitrate and Breast Cancer in the Spanish Multicase-Control Study on Cancer (MCC-Spain). <i>Environmental Health Perspectives</i> , 2016, 124, 1042-1049.	6.0	19
58	Current perspectives of treatment of ductal carcinoma in situ. <i>Cancer Treatment Reviews</i> , 2010, 36, 507-517.	7.7	18
59	Trajectories of alcohol consumption during life and the risk of developing breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1168-1176.	6.4	17
60	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21930-21937.	1.8	17
61	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2007, 33, 474-483.	7.7	16
62	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 381-391.	1.4	16
63	Trastuzumab in small tumours and in elderly women. <i>Cancer Treatment Reviews</i> , 2014, 40, 41-47.	7.7	15
64	Quality of life during treatment in young women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 75-77.	2.5	14
65	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021, 7, 8.	5.2	14
66	Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. <i>Annals of Oncology</i> , 2009, 20, 454-459.	1.2	13
67	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	3.7	13
68	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , 2020, 12, 3132.	4.1	11
69	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. <i>Clinical and Translational Oncology</i> , 2017, 19, 341-356.	2.4	10
70	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. <i>European Journal of Radiology</i> , 2019, 117, 132-139.	2.6	10
71	Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial. <i>Journal of Human Nutrition and Dietetics</i> , 2019, 32, 468-479.	2.5	9
72	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020, 10, 7741.	3.3	9

#	ARTICLE	IF	CITATIONS
73	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
74	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24.	2.8	9
75	Artificial intelligence supporting cancer patients across Europe—The ASCAPE project. <i>PLoS ONE</i> , 2022, 17, e0265127.	2.5	9
76	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	2.8	8
77	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1521.	1.6	8
78	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.1	7
79	Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 1013-1013.	1.6	7
80	Infrequent Loss of Luminal Differentiation in Ductal Breast Cancer Metastasis. <i>PLoS ONE</i> , 2013, 8, e78097.	2.5	6
81	Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). <i>European Journal of Cancer Care</i> , 2020, 29, e13253.	1.5	5
82	Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P). <i>Journal of Clinical Oncology</i> , 2017, 35, 1023-1023.	1.6	5
83	The Use of Taxanes in the Neoadjuvant Treatment of Breast Cancer: A Review of Randomized Phase II/III Trials. <i>Clinical Breast Cancer</i> , 2007, 7, 764-774.	2.4	4
84	Development and validation of a sexual relations satisfaction scale in patients with breast cancer — the SEXSAT-Q. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 143.	2.4	4
85	Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 375-84.	2.4	3
86	A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1114-TPS1114.	1.6	3
87	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. <i>Cancer Research</i> , 2022, 82, P4-10-04-P4-10-04.	0.9	2
88	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. <i>Cancer Research</i> , 2022, 82, P4-07-08-P4-07-08.	0.9	2
89	0145 First safety data from a randomised phase III trial comparing adjuvant epirubicin-cyclophosphamide + docetaxel (EC + T) vs ET + capecitabine (X) in N+ operable breast cancer (BC). <i>Breast</i> , 2009, 18, S55.	2.2	1
90	CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1014-1014.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results.. Journal of Clinical Oncology, 2010, 28, 1143-1143.	1.6	1
92	Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009~05 study.. Journal of Clinical Oncology, 2011, 29, 1008-1008.	1.6	1
93	Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results. Journal of Clinical Oncology, 2005, 23, 735-735.	1.6	1
94	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. Journal of Clinical Oncology, 2014, 32, 11107-11107.	1.6	1
95	Abstract P2-08-17: Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study. Cancer Research, 2019, 79, P2-08-17-P2-08-17.	0.9	1
96	Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL + FUL) versus capecitabine (CAPE).. Journal of Clinical Oncology, 2022, 40, 1019-1019.	1.6	1
97	Scintigraphic Evolution of a Breast Cancer with Tc-99m MIBI Scintimammography. Clinical Nuclear Medicine, 2000, 25, 701-703.	1.3	0
98	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. Breast Cancer Research, 2005, 7, 1.	5.0	0
99	Implementing preoperative endocrine therapy in breast cancer. Lancet Oncology, The, 2020, 21, 1390-1392.	10.7	0
100	Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. Journal of Clinical Oncology, 2021, 39, 3060-3060.	1.6	0
101	Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity.. , 2013, , .		0
102	Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. Journal of Clinical Oncology, 2014, 32, 1602-1602.	1.6	0
103	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. Journal of Clinical Oncology, 2016, 34, 3033-3033.	1.6	0
104	Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.. Journal of Clinical Oncology, 2016, 34, e12504-e12504.	1.6	0
105	Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice. Cancer Research, 2022, 82, P4-11-28-P4-11-28.	0.9	0